UNSPSC 51434809: Leptacline

This classification denotes an antihypertensive agent with the molecular formula C12H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5DXM29256P, chemically known as piperidine, 1-(cyclohexylmethyl)- but generally known as leptacline, which bears US NIH Compound Identifier 71660. European Medicines Agency schedules Leptacline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08436MIG.

UNSPSC 51434809 Leptacline is a Commodity code under which state and local governments procure advanced life support and emergency medications, along with broader pharmaceutical supply agreements serving health systems, fire rescue departments, and state health agencies. The scope of recent solicitations reflects procurement of specific injectable medications (epinephrine, adenosine, diltiazem, labetalol) for emergency medical services, as well as multi-source generic pharmaceuticals and over-the-counter products distributed through state and regional cooperative purchasing vehicles. Issuing bodies include city fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances; the City of Tampa and the Texas Health and Human Services Commission and Minnesota Department of Administration have all posted opportunities under or closely aligned with this code in the past four months.

Recent activity clusters in Texas, Minnesota, and Florida. The City of Tampa issued an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue in Hillsborough County, with a bid due date of April 8, 2026 and an estimated contract value of $40,000, requiring firm pricing inclusive of shipping and applicable taxes with a one-year initial term and two optional one-year renewals. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802) with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with awards effective July 1, 2026. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in early April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs for a future Therapeutic Pharmacy Initiative. MMCAP opportunities carry set-aside and cooperative-purchasing structures; the Tampa solicitation designates a 5 percent bid discount for Small Local Business Enterprise participation (not to exceed $10,000) and requires Safety Data Sheets compliant with OSHA Hazard Communication Standards and WCAG 2.2 Level AA accessibility documentation.